[Staged Hybrid Treatment for a Coronary Artery Pseudoaneurysm after Percutaneous Coronary Intervention;Report of a Case].

We herein report a case of a coronary artery pseudoaneurysm caused by previous catheter intervention, who was treated with a staged hybrid procedure of coronary artery bypass grafting (CABG) and subsequent percutaneous catheter intervention. A 59-year-old man underwent an urgent percutaneous coronary stent placement for acute myocardial infarction at segment 1 of the right coronary artery, where later coronary pseudoaneurysm developed. Prior to closure of the aneurysm by covered stent placement, he underwent CABG to segment 3 using the right internal thoracic artery graft, in case the implanted covered stent should acutely thrombose in the future. The graft flow was increased by producing an artificial stenosis just proximal to the anastomosis. The present technique would be a safe and viable option of therapeutic strategy to fix coronary artery pseudoaneurysms that have been formed at the proximal segment of main coronary arteries.

Ruptured Sinus of Valsalva Aneurysm in a Patient with a Ventricular Septal Defect Who Dropped Out of Lifelong Medical Follow-up.

Ruptured sinus of Valsalva aneurysm (RSOVA) is a rare cardiac condition associated with high morbidity and mortality rates. We herein report a 35-year-old man with a history of ventricular septal defect (VSD). He had a history of interrupted hospital visits and presented to the emergency department with dyspnea, palpitations, and dizziness for a few days. Auscultation detected a continuous murmur. Transthoracic echocardiography followed by transesophageal echocardiography demonstrated RSOVA in the right ventricle with an aorto-right ventricular fistula. The fistula was resected, and the aneurysm was surgically repaired. The patient made a good recovery.

Plasma neutrophil gelatinase-associated lipocalin in acute kidney injury superimposed on chronic kidney disease after cardiac surgery: a multicenter prospective study.

INTRODUCTION: Plasma neutrophil gelatinase-associated lipocalin (NGAL) is reportedly useful for post-cardiac surgery acute kidney injury (AKI). Although chronic kidney disease (CKD) is a strong risk factor for AKI development, no clinical evaluation of plasma NGAL has specifically examined AKI occurring in patients with CKD. This study evaluated plasma NGAL in AKI superimposed on CKD after cardiac surgery. METHODS: This study prospectively evaluated 146 adult patients with scheduled cardiac surgery at 2 general hospitals. Plasma NGAL was measured before surgery, at ICU arrival after surgery (0 hours), and 2, 4, 12, 24, 36, and 60 hours after ICU arrival. RESULTS: Based on the Kidney Disease Improving Global Outcomes (KDIGO) CKD guideline, 72 (49.3%) were diagnosed as having CKD. Of 146 patients, 53 (36.3%) developed AKI after surgery. Multiple logistic regression analysis revealed that preoperative plasma NGAL, estimated glomerular filtration rate (eGFR), and operation time are significantly associated with AKI occurrence after surgery. Plasma NGAL in AKI measured after surgery was significantly higher than in non-AKI irrespective of CKD complication. However, transient decrease of plasma NGAL at 0 to 4 hours was observed especially in AKI superimposed on CKD. Plasma NGAL peaked earlier than serum creatinine and at the same time in mild AKI and AKI superimposed on CKD with increased preoperative plasma NGAL (>300 ng/ml). Although AKI superimposed on CKD showed the highest plasma NGAL levels after surgery, plasma NGAL alone was insufficient to discriminate de novo AKI from CKD without AKI after surgery. Receiver operating characteristics analysis revealed different cutoff values of AKI for CKD and non-CKD patients. CONCLUSIONS: Results show the distinct features of plasma NGAL in AKI superimposed on CKD after cardiac surgery: 1) increased preoperative plasma NGAL is an independent risk factor for post-cardiac surgery AKI; 2) plasma NGAL showed an earlier peak than serum creatinine did, indicating that plasma NGAL can predict the recovery of AKI earlier; 3) different cutoff values of post-operative plasma NGAL are necessary to detect AKI superimposed on CKD distinctly from de novo AKI. Further investigation is necessary to confirm these findings because this study examined a small number of patients.

Successful treatment of cerebral hemorrhage using computed tomography angiography in a patient with left-ventricular-assist device.

Cerebral hemorrhage is one of the common complications associated with left-ventricular-assist device (LVAD) treatment and leads to a high mortality rate because of excessive bleeding due to frequently unknown causes. Cerebral angiography is used to diagnose cerebrovascular events and is well recognized as being very useful for this purpose. We performed a cerebral angiography for a patient with an LVAD who developed cerebral hemorrhage, and the hemorrhagic source was clearly identified. The patient underwent successful neurosurgical treatment, which was followed by heart transplantation.

Thoracoscopic infrared ablation to create a box lesion as a treatment for atrial fibrillation.

BACKGROUND: Creating a box lesion in the posterior wall of the left atrium from the epicardial side of the beating heart remains a challenge. Although a transmural lesion can be created by applying radiofrequency (RF) energy at clampable sites, it is still difficult to create a transmural lesion at unclampable sites because the inner blood flow in the unclampable free wall weakens the thermal effect on the outside. Our aim was to apply the newly developed infrared coagulator to create linear transmural lesions on the beating heart thoracoscopically to treat atrial fibrillation (AF). CASE PRESENTATION: A 71-year-old male was referred to our hospital with a diagnosis of hypertrophic cardiomyopathy and permanent atrial fibrillation. The patient was first diagnosed with atrial fibrillation 20 years before. Direct current cardioversion had been performed every few years a total of four times, but sinus rhythm restoration had always been temporary. On February 27, 2020, thoracoscopic PV isolation together with infrared roof- and bottom-line ablation to create a box lesion and left atrial appendage amputation (LAAA) were performed. The coagulator could be applied to clinical thoracoscopic surgery to successfully create a box lesion without any complication. The patient restored a regular sinus rhythm, it has been maintained for eleven months, and there have been no adverse events. CONCLUSIONS: The infrared coagulator might have enough potential to create transmural lesions on the beating heart in thoracoscopic AF surgery.

Less frequent opening of the aortic valve and a continuous flow pump are risk factors for postoperative onset of aortic insufficiency in patients with a left ventricular assist device.

BACKGROUND: Postoperative development of aortic insufficiency (AI) after implantation of left ventricular assist devices (LVADs) has recently been recognized, but the devices in the previous reports have been limited to the HeartMate I or II. The purposes of this study were to determine whether AI develops with other types of LVADs and to elucidate the factors associated with the development of AI. METHODS AND RESULTS: Thirty-seven patients receiving LVADs without evident abnormalities in native aortic valves were enrolled (pulsatile flow LVAD [TOYOBO]: 76%, continuous flow LVAD [EVAHEART, DuraHeart, Jarvik2000, HeartMate II]: 24%). Frequency of aortic valve opening and grade of AI were evaluated by the most recent echocardiography during LVAD support. None of the patients had more than trace AI preoperatively. During LVAD support AI >- grade 2 developed in 9 patients (24%) across all 5 types of devices. More severe grade of AI correlated with higher plasma B-type natriuretic peptide concentration (r = 0.53, P < 0.01) and with less frequent of the aortic valve (r = 0.45, P < 0.01). Multivariate analysis revealed that lower preoperative left ventricular ejection fraction and a continuous flow device type were independent risk factors for higher incidence of AI. CONCLUSIONS: AI, which is hemodynamically significant, develops after implantation of various types of LVADs. Physicians need to be more alert to the development of AI particularly with continuous flow devices.

Successful treatment of mediastinitis after ventricular assist device implantation with rerouting of the outflow vascular prosthesis.

We report successful treatment of mediastinitis with rerouting of the outflow vascular prosthesis after bi-ventricular assist device (Bi-VAD) implantation. A 23 years-old male with fulminant myocarditis underwent VAD implantation. He required sternotomy three times. Mediastinitis developed after the third surgery, and negative pressure wound therapy (NPWT) with irrigation was applied. The infection was well controlled, but after 3 months of NPWT hemorrhage developed because of injury of the outflow vascular prosthesis in the anterior mediastinum. We rerouted the outflow vascular prosthesis to the descending aorta via the left thoracic cavity. After rerouting, artificial material was removed from the anterior mediastinum. The sternal wound healed completely after NPWT. Intractable mediastinitis after extra-corporeal VAD implantation may be treated with irrigation and NPWT, but there is a possibility of outflow graft injury. A sternal wound could be closed as a secondary healing process by rerouting the outflow vascular prosthesis.

Negative pressure wound therapy for left ventricular assist device-related mediastinitis: two case reports.

We report two cases of successful use of negative pressure wound therapy (NPWT) to control of left ventricular assist device (LVAD)-related mediastinitis. It is difficult to treat mediastinitis in patients who have undergone LVAD implantation, because it is impossible to remove the infected artificial materials from the mediastinal space. This report indicates that NPWT might become the preferred therapeutic option for control of mediastinitis in patients who have undergone LVAD implantation.

Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy.

Anthracyclines are effective antineoplastic drugs, but they are known to be cardiotoxic. Recovery of cardiac function is rare. A few studies on implantation of a ventricular assist device (VAD) have been performed for anthracycline-induced cardiomyopathy. Recovery of left ventricular (LV) function with an LVAD is also rare. Recently, several adjunctive therapies were attempted to restore ventricular function. We report a successful bridge to recovery of ventricular function using VAD implantation for anthracycline-induced cardiomyopathy. The patient was a 57-year-old man who had been diagnosed with diffuse large B-cell lymphoma (DLBCL) at age 52. Combination chemotherapy including hydroxydaunorubicin was started. Complete remission was achieved after chemotherapy. Heart failure symptoms such as fatigue, dyspnea on exertion, and weight gain appeared 5 months later. A cardiac resynchronization device was implanted. His heart function deteriorated. He underwent implantation of a Toyobo LVAD and mitral annuloplasty. After implantation, he was prescribed carvedilol with spironolactone. He was weaned from the LVAD on postoperative day (POD) 239 and discharged on POD 37 after weaning. He remained in New York Heart Association classes within the first- to second-degree range, the LV dimention diastolic/systolic ratio was 56/46 mm, ejection fraction 38%, and mitral regurgitation mild at 3 years after weaning from the LVAD. Our patient could be weaned from LVAD probably due to the combination management strategy employing mitral valvuloplasty, use of cardiac resynchronization therapy, and taking carvedilol with spironolactone. Further studies will be needed to clarify the efficacy of these adjunctive therapies.

Use of DuraHeart® support for more than 1 year as the first successful bridge to heart transplantation in Japan.

We report the first successful case in Japan of use of a DuraHeart(®) for 437 days as a bridge to heart transplantation. A 55-year-old woman developed dilated cardiomyopathy at the age of 47. Her heart condition gradually deteriorated, and she became dependent on catecholamine support, therefore a DuraHeart(®) was implanted. She had an uncomplicated postoperative course, and was discharged on postoperative day (POD) 54. Only once, the alarm of the controller of the DuraHeart(®) gave a problem, and had to be replaced. She had no adverse events while she awaited heart transplantation as an outpatient. She underwent heart transplantation on POD 437. Strong adhesion of the drive line to the liver and peritoneal membrane made resection difficult. No thrombus formation was found inside the DuraHeart(®), but a wedge thrombus was observed around the inflow cannula in the left ventricle. She was discharged on POD 38 after the transplantation.

Prolonged biventricular assist device support as a bridge to heart transplantation.

We report a case in which long-term biventricular assist device (BiVAD) support enabled successful heart transplantation. The patient was diagnosed with dilated cardiomyopathy at age 11. She underwent implantation of a Toyobo LVAD, tricuspid valvuloplasty and annuloplasty at age 15. Right heart bypass (RHB) was established using a centrifugal pump. Right ventricular function showed no improvement during a ten-day period, and RHB was switched to a Toyobo RVAD on postoperative day (POD) 11. Because of poor oxygenation, veno-venous extracorporeal membrane oxygenation (V-V ECMO) was instituted. She was weaned from V-V ECMO on POD 14. She was brought to the United States on POD 189 under BiVAD support, and underwent heart transplantation on POD 199. She was discharged 4 months later. Two years after heart transplantation, she remained in New York Heart Association class one without rejection.

Purulent pericarditis-induced intracardiac perforation and infective endocarditis due to Parvimonas micra: a case report.

BACKGROUND: Purulent pericarditis, a rare disease with a high associated mortality rate in patients without adequate treatment, can cause serious complications, such as perforation of the surrounding tissue and organs. Parvimonas micra is a very rare cause of purulent pericarditis. CASE SUMMARY: A 70-year-old male patient presented to our emergency room with chest pain of 10 days' duration. An electrocardiogram showed ST-segment elevation and PR-segment depression on multiple leads. A transthoracic echocardiogram showed normal left ventricular function and a large amount of pericardial effusion. Acute pericarditis was diagnosed, and anti-inflammatory drug therapy was initiated. Due to the lack of improvement in the symptoms, pericardiocentesis was performed on Day 8 and revealed about 800 cc of the bloody fluid. Parvimonas micra was detected in a culture of the pericardial effusion and blood. Although intravenous antibiotic therapy was initiated for purulent pericarditis, his fever persisted. Computed tomography of the chest performed on Day 14 showed an abscess cavity in the pericardial space around the right atrium (RA). Furthermore, transoesophageal echocardiography revealed vegetation in the RA. Emergency surgery confirmed the presence of vegetation and minor perforation of the RA with communication to the abscess cavity. After surgical therapy, the patient clinically improved and was discharged on Day 51. DISCUSSION: In cases of acute pericarditis, purulent pericarditis should be considered if clinical improvement is not observed after initial treatment with anti-inflammatory drugs. Once the diagnosis of purulent pericarditis is made, aggressive source control is necessary for improved clinical outcomes.

New pre-clotting method for fibrin glue in a non-sealed graft used in an LVAD: the KYO method.

Pre-clotting has been applied to a vascular prosthesis with high permeability (non-sealed graft). In this study, conventional pre-clotting methods were compared with our novel method, which keeps high-yield optimization of hemostasis, the KYO method. Fibrinogen solution (A) and thrombin solution (B) of fibrin glue (Beriplast P Combi-Set(®)) were applied to the graft (Cooly low-porosity woven graft) by five methods; Group 1: control, without fibrin glue; Group 2: spray method, spraying solutions A and B simultaneously; Group 3: rub method, rubbing solution A first, and then rubbing solution B on the graft; Group 4: rub-and-spray method, rubbing solution A on the graft, then spraying solutions A and B; Group 5: the KYO method, rubbing solution A into the graft with the finger, then rubbing solution B on the graft. Burst pressure, the point of saline solution leakage, was measured 10 times for each group. The grafts were microscopically examined using HE staining and electron microscopy. The average burst pressure was 12.6 ± 1.5 mmHg in Group 1, 27.1 ± 3.3 mmHg in Group 2, 22.4 ± 7.1 mmHg in Group 3, 41.0 ± 9.0 mmHg in Group 4, and 300 mmHg in Group 5. Saline solution did not leak through the graft at a pressure of 300 mmHg in Group 5. There were statistically significant differences among the groups. The relationship between fibrin glue and the graft was unclear in all groups by HE staining. Electron microscopic photographs showed a smooth surface and fibrin glue permeating the graft fibers in Group 5. The KYO method was better than the others in terms of resistance to pressure. It was a very simple method, and could thus come into widespread use.

Outcomes of midterm circulatory support by left ventricular assist device implantation with descending aortic anastomosis.

For some patients undergoing left ventricular assist device (LVAD) implantation, the perfusion tube is anastomosed to the descending aorta instead of the currently more prevalently used ascending aorta. Purpose of this study was to assess retrospectively the outcomes of LVAD patients with descending aortic anastomosis. Between March 2007 and March 2010, six patients underwent LVAD implantation with descending aortic anastomosis with Toyobo or Jarvik 2000 LVAD at our institute. Their average circulatory support time was 434 (range 82-751) days. Both types of LVAD afforded adequate circulatory support, and inotrope treatment and mechanical ventilation were discontinued relatively early. Echocardiograms of the three patients with Jarvik 2000 LVAD revealed antegrade flow in the ascending aorta during the intermittent low-speed period. Among them, one patient developed infarction in the right brain hemisphere because of thromboembolism, whereas another patient developed pneumonia in the left lung followed by a lethal systemic infection. One patient on Toyobo LVAD support reached heart transplantation without morbidity. Another patient implanted with Toyobo LVAD, whose left ventricular function was too poor to generate forward flow through aortic valve, developed thrombus in the ascending aorta. No embolic events were observed in the organs below the diaphragm. In conclusion, descending aortic anastomosis of the perfusion tube can be used for LVAD implantation for some patients, but considerable risks of morbidities, including thromboembolic events and/or infection, should be recognized.

Thrombotic occlusion of the ascending aorta after Toyobo LVAD implantation with descending aortic perfusion in a post-Bentall patient.

A 35-year-old patient in whom a Toyobo left ventricular assist device (LVAD) was implanted with descending aortic perfusion for the treatment of critical heart failure due to global myocardial infarction after repeat aortic root operations with a mechanical aortic valve developed complete thrombotic occlusion of the ascending aorta. This phenomenon was supposedly brought about by the patient's left ventricular contraction being too poor to open the mechanical aortic valve. The patient has, however, been doing well under LVAD support, with no thromboembolic events occurring for at least 2 years since the device was implanted.

A novel external counterpulsation system for coronary artery disease and heart failure: pilot studies and initial clinical experiences.

External counterpulsation (ECP) is a beneficial and noninvasive treatment for coronary artery disease or heart failure; however, it still has a lot of limitations. We used a novel ECP system, Compact CP, the main feature of which is the double-lumen cuff that reduces the impact of cuff inflation and the size of the air compressor. The first lumen was a contact cuff that was attached to the legs with a constant pressure (8 kPa). The second lumen was a main cuff that was inflated and deflated with a driving pressure and synchronized to the cardiac cycle. In this report, we describe the results of four pilot studies in a total number of 39 healthy volunteers and initial clinical experiences of this system in three patients. The pilot studies demonstrated that the ECP system provided significant diastolic augmentation and systolic unloading. It also achieved a satisfactory diastolic/systolic pressure ratio (1.00 ± 0.06) with a high comfort level at a driving pressure of 40 kPa. Higher pressure (50-70 kPa) increased the assist performance but decreased the comfort level. ECP was also applied with a patient with chronic refractory angina and two patients with postoperative heart failure following cardiac surgery. The clinical conditions improved. No adverse effect was observed. Our novel ECP system is safe, effective, and promising in the treatment of coronary artery disease or heart failure. Further clinical investigations are needed to support the significance of this system.

Thoracoscopic stapler-closure of left atrial appendage and epicardial clamp-isolation of pulmonary veins in a patient with non-valvular atrial fibrillation and short bowel: a case report.

BACKGROUND: Thromboembolic occlusion of the superior mesenteric artery (SMA) is a serious event in patients with atrial fibrillation (AF). Extensive bowel resection is frequently required, and the resulting short bowel syndrome hampers the intake of anticoagulant or anti-arrhythmic medication. CASE SUMMARY: We report the case of thoracoscopic surgery consisting of stapler-closure of the left atrial appendage and bilateral epicardial clamp-isolation of the pulmonary veins performed in a 66-year-old male patient with symptomatic persistent non-valvular AF who became unable to take in anticoagulants or anti-arrhythmic drugs because of thromboembolic SMA occlusion and subsequent total resection of the small intestine. The patient has been free from thromboembolic or arrhythmic symptoms during 6 months of follow-up despite taking no anticoagulant or anti-arrhythmic drugs. Electrocardiographic monitoring demonstrated a stable sinus rhythm for 48 h at postoperative Months 3 and 6. Echocardiography manifested an improvement of the left ventricular ejection fraction from a preoperative value of 44-69% at postoperative Month 6. DISCUSSION: The present technique may contribute to treating patients with symptomatic non-valvular AF and a complication similar to that of the present case.

En Bloc Left Pulmonary Vein and Appendage Isolation in Thoracoscopic Surgery for Atrial Fibrillation.

BACKGROUND: We evaluated the safety and rhythm control effectiveness in en bloc isolation of the left pulmonary vein (PV) and appendage conducted as part of the thoracoscopic procedure for bilateral PV isolation, non-PV ablation, and appendage closure for atrial fibrillation (AF). METHODS: Procedural safety was evaluated by reviewing the surgical records. Rhythm control was examined in accordance with the Heart Rhythm Society guidelines at postoperative months 1, 3, 6, and 12, and yearly thereafter. The sinus rhythm rates at postoperative years 1 and 2 were compared with the corresponding data from our previous procedure without the en bloc technique. RESULTS: Starting in 2014, the en bloc technique was applied to 238 nonvalvular AF patients and successfully performed in all but 23 patients. The mean operation time was 88 minutes. There were no hospital deaths or major procedure-related complications. The mean follow-up period was 1.7 years. The sinus rhythm rates at postoperative years 1 and 2 were 85% and 80% in paroxysmal, 76% and 70% in persistent, and 67% and 61% in long-standing persistent AF, respectively, without antiarrhythmic drug use. Compared with the previous procedure (n = 324), sinus rhythm rates were higher in long-standing persistent AF (67% vs 50% at 1 year and 61% vs 40% at 2 years; p = 0.04). No patients suffered cardiogenic thromboembolisms without anticoagulation. CONCLUSIONS: Thoracoscopic en bloc left PV and appendage isolation was safely achieved in most patients. Using this technique may contribute to better rhythm control results than not using it in cases of long-standing persistent AF.

Thoracoscopic stapler-and-loop technique for left atrial appendage closure in nonvalvular atrial fibrillation: Mid-term outcomes in 201 patients.

BACKGROUND: Left atrial appendage (LAA) closure can be an alternative to oral anticoagulation to prevent cardiogenic thromboembolisms in patients with nonvalvular atrial fibrillation. OBJECTIVE: The purpose of this study was to retrospectively evaluate the safety, completeness, and mid-term prevention of our thoracoscopic stapler-and-loop technique for LAA closure. METHODS: Patients operated on between October 2008 and February 2017 were reviewed. Endoscopic stapler and ligation loops were used. Patients received 1 month of anticoagulation before discontinuation. Hospital death and procedure-related major complications (thromboembolism, hemorrhagic events, phrenic palsy) were the primary composite endpoint for safety, and cardiogenic thromboembolisms were the endpoint for prevention. Brain magnetic resonance imaging investigated new thromboembolic spots 1 year after surgery. RESULTS: There were 201 patients (118 men, 83 women) with a mean age of 74 years (range 68-94) years, mean CHA2DS2-VASc score (± SD) 4.1 ±1.4, and mean HAS-BLED score 2.9 ± 1.0. Mean operation time was 28 minutes. All LAAs were removed, and intraoperative transesophageal echocardiography confirmed completeness of the closure in each patient. No hospital deaths or major procedure-related complications occurred. Follow-up results for 198 patients (98%) over a mean period of 48 months (range 12-110) revealed that 2 patients developed cardiogenic thromboembolisms (0.25 event per 100 patient-years). Magnetic resonance imaging of 51 patients with a mean CHA2DS2-VASc score of 4.7 ± 1.6 revealed 1 new small spot in each of 2 patients (3.9%; 3.9 spots per 100 patient-years). CONCLUSION: Our thoracoscopic stapler-and-loop technique swiftly, safely, and completely closed LAAs in patients with nonvalvular atrial fibrillation and provided acceptable mid-term prevention without anticoagulation.